The FDA fast track designation plus the double bottom in the stock chart plus the shorts that will have to cover... this should lead to a rising stock price!
L
Someone dumped 4M shares at the bell..?
F
NOTHING below $10.............a world class., new antibiotic......!!!! INCREDIBLE facts ., for the company and the world. CONGRATULATIONS TO SCIENTISTS BEHIND AND MANAGEMENT.
F
btw---------WITH AN AVERAGE OF $18,BY ANALYSTS............AMAZING.
P
Shorts are in full control. Until they ain't
But access into NTM market makes this a 500 Million MKT Cap company down the line. If not a Billion
90 million currently lol
Plus it really helps treat this ailment & its caregivers & that's a good thing if you still have a soul
K
Paul is 100% correct...shorts have been in complete control since 2017.
F
NOTHING ABOUT ALCOHOL..........NON-TUBERCULOUS PULMONARY DISEASES.........WORLD WIDE RANGE OF PULMONARY DISEASES.........BILLIONS POTENTIAL.
C
~14% day on zero news!? Hmm
K
Shorts also get margin calls. You better cover soon.
F
Just to develop and reach all FDA approvals ....they used almost $400 MILLIONS........ today with a $100 M Market cap........ridiculous. BIG pharma.....should buy us!!!!
Record number of Scripts written each week… cant overlook that!! Going to be a strong Q2 One of the largest shareholders is “Blackrock”..
n
What index fund is Paratek on if any presently.
I
Break out numbers for PRTK Highly excited about this and for Q2 numbers and beyond !!
scripts rocket up to 185 and Revenues break $ 2 Million For The Week revenues new record $$$$ 2.06 Million
m
(ADIL) $1.30 --MCap $30 mil --- Blockbuster Phase 3 results imminent ( in June) = $$$$$$$$$$$$$$$$ "Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter"
####
L
Marc. You are correct, I didn't include PRTK debt load. I also didn't include their 80-90 million on hand. As you noticed, in the last ER, rev projections for 2022 were 155-170 million which is more than the present mc. I still feel that PRTK at these levels is very undervalued and will rebound to reflect closer to the true value of the company. With the 1000 pt. drop of the market yesterday, PRTK didn't follow the market to that level. Looks like we could be at the bottom, but for how long? Thats a hard one to predict. Buvay!
L
I know that the antibiotic sector is not as flashy as new/improved cancer meds... but they are still needed. PRTK has N used for increasing indications with increasing revs. Trading at these levels seems like a screaming buy. I have to believe that some larger company has looked at PRTK for a bolt on buy out. Collaborators Zai Lab and AbbVie (Allergen) could write the check for $500 million and pay that off that bill easily in 3 years with the present sales force. With these large pharma's and seasoned sales reps, I would expect sales to expand much faster. PRTK does have just the 2 products, N and S, and both are pretty straight forward marketing products. Oh, $500 million would net an aprox. share price o $9.30, which I think most share holders would take. If this is not the case, with sales of $120 million a year, the share price should be about $6.50 if not higher. To take a stake in this company at these level's should be fairly rewarde in the near future. Just my take on this, nothing more. Cheers.
d
This is a $20+ company. Have patience
J
Nothing but pump and dump
V
The market is in a sell off mode. Too many dooms day predictions. Everything will be much better soon as we all realize the world has not ended.
INCREDIBLE facts ., for the company and the world.
CONGRATULATIONS TO SCIENTISTS BEHIND AND MANAGEMENT.
But access into NTM market makes this a 500 Million MKT Cap company down the line. If not a Billion
90 million currently lol
Plus it really helps treat this ailment & its caregivers & that's a good thing if you still have a soul
BIG pharma.....should buy us!!!!
One of the largest shareholders is “Blackrock”..
Highly excited about this and for Q2 numbers and beyond !!
scripts rocket up to 185 and Revenues break $ 2 Million For The Week
revenues new record $$$$ 2.06 Million
"Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of
Alcohol Use Disorder; on track to report Phase 3 results in the current quarter"
####